Cancer discoveryHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaImidazolesClinical TrialsPhase III as Topic
Phase III Data Support Chemo-Free Approach to ALL.
Published: 202610.1158/2159-8290.CD-NW2025-0110
Abstract
In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblast…
Preview only. Read the full abstract at the source